Clinically, VRK1 expression has been associated with high grade and poor prognosis in patients with glioma (26), whereas VRK2 expression is correlated with improved survival in high-grade astrocytoma (27). The gene discussed is VRK1; the disease is astrocytoma (excluding glioblastoma).